Valrubicin (N-trifluoroacetyladriamycin-14-valerate), a semisynthetic analog of the anthra-cycline doxorubicin, is a cytotoxic agent.
VALSTAR is indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.
Media Articles Related to Valstar (Valrubicin)
Bladder Cancer: Catching Up at Last
Source: Medscape Hematology-Oncology Headlines [2014.09.08]
Bladder cancer is poised to become the next cancer success story, says Dr. Matthew Galsky, who sees emerging targeted therapies and patient selection as the new hallmarks of successful treatment.
Testing for invisible blood in urine to diagnose bladder cancer
Source: Urology / Nephrology News From Medical News Today [2014.09.03]
New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians.
Identifying bladder cancer patients who could benefit from 'tumor-softening' treatment
Source: Radiology / Nuclear Medicine News From Medical News Today [2014.08.02]
Scientists in Manchester have identified a protein that could help doctors decide which bladder cancer patients would benefit from a treatment that makes radiotherapy more effective, according to a...
Dogs and humans will benefit if research leads to new bladder cancer assay
Source: Veterinary News From Medical News Today [2014.06.09]
Veterinary researchers at Oregon State University have identified a unique group of proteins that indicate the presence of transitional cell carcinoma - the most common cause of bladder cancer - and...
Exercise Linked to Improved Bladder Cancer Survival
Source: MedicineNet Bladder Cancer Specialty [2014.05.22]
Title: Exercise Linked to Improved Bladder Cancer Survival
Category: Health News
Created: 5/21/2014 2:36:00 PM
Last Editorial Review: 5/22/2014 12:00:00 AM
Published Studies Related to Valstar (Valrubicin)
Factors affecting valrubicin response in patients with bacillus Calmette-Guerin-refractory bladder carcinoma in situ. [2011.05]
OBJECTIVE: Patients with bacillus Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the bladder are candidates for intravesical (IVe) valrubicin. This post-hoc analysis of data from the pivotal phase 3, prospective, open-label study of valrubicin evaluated the effects of patient characteristics and past treatments on the response to valrubicin... CONCLUSIONS: In these patients with BCG-refractory CIS, complete responders to valrubicin did not differ significantly from partial or nonresponders in the number of prior courses or instillations. The results suggest that therapy with valrubicin may be considered in appropriate candidates who have not responded to prior therapies. Cystectomy should be reconsidered when valrubicin treatment fails.
Topical application of valrubicin has a beneficial effect on developing skin tumors. [2010.08]
Valrubicin is a second generation anthracycline characterized by an excellent safety profile presenting no skin toxicity or necrosis upon contact...
Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model. [2010.02]
Valrubicin is a cytostatic drug currently approved by the American Federal Drug Administration as a trademarked Valstar sterile solution for the treatment of bladder cancer. Valrubicin has shown an excellent therapeutic potential with minimal toxicity.
Clinical Trials Related to Valstar (Valrubicin)
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma [Recruiting]
The purpose of this study is to learn more about how well the drug valrubicin (VALSTARŪ)
works to help treat the patient's cancer when administered through a nephrostomy tube
inserted through their back into their kidney. The study is also being done to determine how
safe and easy it is to tolerate valrubicin at specific dose levels, as well as the way in
which the drug is eliminated from the human body (Pharmacokinetics or PK).
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer [Not yet recruiting]
The use of a designed viral vector that can destroy cancer cells while leaving normal cells
largely unharmed. The virus also stimulates an immunological response by producing a special
factor (GM-CSF) to attract and promote the development of dendritic and T effector cells. It
forms the hypothesis that this regimen may be used for people who have failed current forms
of treatment and are recommended for cystectomy. It is with hope that this novel therapy
will be able to delay or potentially avoid cystectomy for this patient population. Bladder
instillation of this agent causes little long lasting side effects and may drastically
improve the stimulation of the immune system for local cancer cell death as well as
destroying those tumor cells that may have travelled to regional lymph nodes or distant